Fig. 3. LCH binds with EGFR and inhibits EGFR and AKT kinase activity. (A) LCH structure. (B) In vitro ADP-Glo kinase assay was performed using EGFR kinase enzyme system. Gefitinib used as a positive control. The values indicated mean ± SD. (C) In vitro ADP-Glo kinase assay was performed using AKT1 and AKT2 kinase enzyme system. MK2206 used as a positive control. The values indicated mean ± SD. Data are presented as the mean ± SD. **p<0.01, or ***p<0.001 compared to the controls. (D-F) The predicted binding sites of LCH in EGFR (D), AKT1 (E) and AKT2 (F). The ATP binding pockets of both kinases, shown with surface representation, were occupied tightly by LCH (spheres). The binding pockets were zoomed in. LCH (light pink) and the amino acids (purple) in 4 Å are drawn with sticks. Those amino acids with possible hydrophobic interactions are circled.
© Biomolecules & Therapeutics
